Albireo Pharma Inc P / E
Was ist das P / E von Albireo Pharma Inc?
P / E von Albireo Pharma Inc ist 0.00
Was ist die Definition von P / E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P / E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Albireo Pharma Inc
Was macht Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Unternehmen mit p / e ähnlich Albireo Pharma Inc
- Richland Resources International hat P / E von N/A
- Safeplus International hat P / E von N/A
- China Yanyuan Yuhui Natl Ed Grp hat P / E von N/A
- Acusphere hat P / E von N/A
- American Oriental Bioengineering hat P / E von N/A
- Gourmet Provisions International hat P / E von N/A
- Albireo Pharma Inc hat P / E von 0.00
- SEL Manufacturing hat P / E von 0.00
- China Zhong Qi Hldgs hat P / E von 0.00
- MedSmart hat P / E von 0.00
- Panbela Therapeutics hat P / E von 0.00
- Epic hat P / E von 0.00
- 2574 hat P / E von 0.00